Recent developments with Sarepta Therapeutics Inc (SRPT) have led to the company’s beta value being reach 0.80 cents.

A new trading day began on Tuesday, with Sarepta Therapeutics Inc (NASDAQ: SRPT) stock price down -0.51% from the previous day of trading, before settling in for the closing price of $124.37. SRPT’s price has ranged from $55.25 to $173.25 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 32.89%. Meanwhile, its annual earnings per share averaged 133.57%. With a float of $89.52 million, this company’s outstanding shares have now reached $93.73 million.

The extent of productivity of a business whose workforce counts for 1314 workers is very important to gauge. In terms of profitability, gross margin is 87.71%, operating margin of 2.52%, and the pretax margin is 4.13%.

Sarepta Therapeutics Inc (SRPT) Insider and Institutional Ownership

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Sarepta Therapeutics Inc is 6.13%, while institutional ownership is 92.36%. The most recent insider transaction that took place on Aug 30 ’24, was worth 822,100. In this transaction Chief Financial Officer of this company sold 5,985 shares at a rate of $137.36, taking the stock ownership to the 33,946 shares. Before that another transaction happened on Aug 30 ’24, when Company’s Officer proposed sale 5,985 for $137.37, making the entire transaction worth $822,130.

Sarepta Therapeutics Inc (SRPT) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around 133.57% per share during the next fiscal year.

Sarepta Therapeutics Inc (NASDAQ: SRPT) Trading Performance Indicators

Here are Sarepta Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.84.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.40, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 11.23 in one year’s time.

Technical Analysis of Sarepta Therapeutics Inc (SRPT)

The latest stats from [Sarepta Therapeutics Inc, SRPT] show that its last 5-days average volume of 0.82 million was inferior to 1.26 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 82.07%. Additionally, its Average True Range was 3.61.

During the past 100 days, Sarepta Therapeutics Inc’s (SRPT) raw stochastic average was set at 21.82%, which indicates a significant decrease from 64.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.59% in the past 14 days, which was lower than the 56.08% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $129.63, while its 200-day Moving Average is $129.22. Now, the first resistance to watch is $124.73. This is followed by the second major resistance level at $125.74. The third major resistance level sits at $126.49. If the price goes on to break the first support level at $122.97, it is likely to go to the next support level at $122.22. The third support level lies at $121.21 if the price breaches the second support level.

Sarepta Therapeutics Inc (NASDAQ: SRPT) Key Stats

With a market capitalization of 11.80 billion, the company has a total of 94,524K Shares Outstanding. Currently, annual sales are 1,243 M while annual income is -535,980 K. The company’s previous quarter sales were 362,930 K while its latest quarter income was 6,460 K.